Pitfall in Management of BPH
Keywords:
Pitfall, Management, BPHAbstract
-
References
Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-9.
Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America Project: benign prostatic hyperplasia. J Urol 2005; 173: 1256-61.
Garraway WM, Russell EBAW, Lee RJ, et al. Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men. Br J Gen Pract 1993; 43: 318-21.
Gjertson CK, Walmsley K, Kaplan SA. Benign prostatic hyperplasia: now we can begin to tailor treatment. Cleveland clin j med 2004; 71(11): 857-80.
Narayan P, Tewari A. Overview of alpha-blocker therapy for benign prostatic hyperplasia. Urology 1998; 51(suppl 4A): 38-45.
Lepor H, Gup DI, Baumann M, Shapiro E. Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia. Urology 1988; 32(suppl): 21-6.
Cabelin MA, Te AE, Kaplan SA. Benign prostatic hyperplasia: challenges for the new millennium. Curr Opin Urol 2000; 10: 301-6.
Rhodes T, Girman CJ, Jacobsen SJ, Roberts RO, Guess HA, Lieber MM. Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J Urol 1999; 161: 1174-9.
Speakman MJ, Kirby RS, Joyce A, Abrams P, Pocock R. Guideline for the primary care management of male lower urinary tract symptoms. BJU 2004; 93: 985-90.
Su L, Guess HA, Girman CJ, et al. Adverse effects of medications on urinary symptoms and flow rate: a community-based study. J Clin Epidemiol 1996; 49: 483-7.
AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003; 170: 530-47.
Beckman TJ, Mynderse LA. Evaluation and Medical Management of Benign Prostatic Hyperplasia. Mayo Clin Proc 2005; 80(10): 1356-62.
Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostatic specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999; 53: 581-9.
Jacobsen SJ, Jacobson DJ, Girman CJ, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997; 158: 481-7.
Choong S, Emberton M. Acute urinary retention. BJU Int 2000; 85: 186-201.
Murray K, Massey A, Feneley RC. Acute urinary retention-a urodynamic assessment. Br J Urol 1984; 56: 468-73.
McNeill SA. The role of alpha-blockers in the management of acute urinary retention caused by benign prostatic obstruction. Eur Uro 2004; 45: 325-32.
Henderson JS. Intermittent clean self-catheterization in clients with neurogenic bladder resulting from multiple sclerosis. J Neurosci Nurs 1989; 21: 160-4.
Horgan AF, Prasad B, Waldron DJ, OûSullivan DC. Acute urinary retention. Comparison of suprapubic and urethral catheterisation. Br J Urol 1992; 70: 149-51.
Ichsan J, Hunt DR. Suprapubic catheters: a comparison of suprapubic versus urethral catheters in the treatment of acute urinary retention. Aust N Z J Surg 1987; 57: 33-6.
Hastie KJ, Dickinson AJ, Ahmad R, Moisey CU. Acute retention of urine: is trial without catheter justiied ? J R Coll Surg Edinb 1990; 35: 225-7.
Djavan B, Madersbacher S, Klingler C, Marberger M. Urodynamic assessment of patients with acute urinary retention: is treatment failure after prostatectomy predictable. J Urol 1997; 158: 1829-33.
McNeill SA, Hargreave TB, Roehborn CG. Alfuzosin 10 mg once daily in the management of acute urinary retention: Results of a double-blind placebo-controlled study. Urology 2005; 65: 83-9.
Pickard R, Emberton M, Neal DE et al. The management of men with acute urinary retention. Br J Urol 1998; 81: 712-20.25. McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-98.
Milani S, Djavan B. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on alpha-1 adrenoceptor antagonist. BJU intl 2005; 95(suppl 4): 29-36.
Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36: 1-13.
Abrams P, Schater W, Tammela TL, et al. Finasteride Urodynamics Study Group, Improvement of pressure flow parameter with finasteride is greater in men with large prostate. J Urol 1999; 161: 1513-7.
Cabelin MA, Te AE, Kaplan SA. Benign prostatic hyperplasia: challenges for the new millennium. Curr Opin Urol 2000; 10: 301-6.
Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215-24.
Rosier PF, de la Rosette JJ, Wijkstra H, Van Kerrebroeck PE and Debruyne FM. Is detrusor instability in elderly males related to the grade of obstruction? Neurourol Urodyn 1995; 14: 625-33.
Athanasopoulos A, Gyftopoulos K, Giannitsas J, Fisfis P, et al. Combination treatment with alpha-blocker plus an anticholinergic for bladder outlet obstruction : A prospective, randomized, controlled study. J Urol 2003; 169: 2253-6.
